Full Press Release Details
Immutep Quarterly Activities Report Q1 FY25.
IMMP
Immutep Quarterly Activities Report Q1 FY25
Key Takeaway: Immutep Quarterly Activities Report Q1 FY25
Price reaction · baseline $1.9 (2024-10-25 close) · 1 other IMMP headline(s) in the window, move may be shared
day 0 close
+0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)